title: [Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].
abstract: OBJECTIVE
  Enzalutamide and abiraterone represent new therapeutical options in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the presented study was retrospective analysis of clinical experience and efficacy of enzalutamide or abiraterone in the postchemo indication in patients with mCRPC.
  
  
  METHODS
  A total of 32 mCRPC patients were evaluated. All patients received one or more lines of chemotherapy. Twenty-three patients were treated by enzalutamide, nine patients were treated by abiraterone. We defined two parameters: over all survival and progression-free survival.
  
  
  RESULTS
  The median follow-up was 6.5 months. A total of 10 patients treated by enzalutamide progressed (43.47%) and eight patients died (34.78%). A total of five patients treated by abiraterone progressed (55.56%) and one patient died (11.11%). We did not observe any statistical difference in over all survival (HR 0.2362, 95% CI 0.0295- 1.8942; p = 0.102) and in progression-free survival (HR 0.9853, 95% CI 0.2934- 3.308; p = 0.939) between enzalutamide and abirateron.
  
  
  CONCLUSIONS
  Our retrospective study demonstrated similar efficacy of enzalutamide and abiraterone in mCRPC patients previously treated by chemotherapy.
authors.forename: I
authors.initials: I
authors.lastname: Richter
authors.forename: J
authors.initials: J
authors.lastname: Dvořák
authors.forename: V
authors.initials: V
authors.lastname: Hejzlarová
authors.forename: J
authors.initials: J
authors.lastname: Chalupa
authors.forename: M
authors.initials: M
authors.lastname: Sochor
authors.forename: I
authors.initials: I
authors.lastname: Stankuš
authors.forename: L
authors.initials: L
authors.lastname: Barsová
authors.forename: M
authors.initials: M
authors.lastname: Holikova
authors.forename: J
authors.initials: J
authors.lastname: Forster
authors.forename: J
authors.initials: J
authors.lastname: Bartoš
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000736:Androstenes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies
chemical_list: D000736:Androstenes; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide; C089740:abiraterone